#USA #New York #Class Action #Levi Korsinsky #aTyr Pharma

Legal Alert: Class Action Lawsuit Filed Against aTyr Pharma

Overview

Levi & Korsinsky, LLP has recently informed the shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) about a class action lawsuit. This legal action is based on allegations of securities fraud, with a specific focus on the company's actions and statements that affected investor confidence and share value. The lawsuit is particularly relevant for any investors who held shares during the defined period between November 7, 2024, and September 12, 2025.

Allegations

The core allegations in the lawsuit revolve around aTyr dismissing or failing to disclose critical information concerning the efficacy of their drug, Efzofitimod. Initially marketed as a treatment that would allow patients to significantly reduce or taper their steroid usage, the company faced backlash after the study results indicated otherwise. Following a disappointing announcement on September 15, 2025, which revealed that the study did not meet its primary endpoint, aTyr's share price plummeted from $6.03 to $1.02 in a single day—an astonishing 83.2% decline.

Next Steps for Shareholders

Affected shareholders who wish to be part of this class action have until December 8, 2025, to request that the court appoint them as lead plaintiffs. Notably, participation in any potential recovery from this lawsuit does not necessitate serving as a lead plaintiff, thereby allowing more flexibility for interested investors. Importantly, there is no financial obligation for those who join the case, as class members typically have the right to recover losses without incurring out-of-pocket costs related to the legal process.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has a longstanding reputation for championing shareholders' rights. With over 20 years of experience in complex securities litigation, the firm has successfully recovered hundreds of millions of dollars for investors in various cases. With a robust team of over 70 legal professionals, they bring extensive expertise and resources to the forefront of this lawsuit. The firm has consistently ranked as one of the leading securities litigation firms in the United States according to ISS Securities Class Action Services.

Contact Information

For those interested in joining the lawsuit or seeking more information, they can reach out directly to the firm via:

• - Email: [email protected]
• - Phone: (212) 363-7500

As the legal landscape continues to evolve, shareholders of aTyr Pharma, Inc. are encouraged to carefully evaluate their position and consider the implications of this class action lawsuit. This case highlights the importance of transparent communication from publicly traded companies and the potential ramifications for investors when that transparency is compromised. Without a doubt, as this lawsuit unfolds, it will serve as a critical reminder of the need for diligence and awareness in investment decisions.